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ABSTRACT
THE EFFECTS OF MENOPAUSAL VASOMOTOR SYMPTOMS AND CHANGES IN
ANTHROPOMETRY ON BREAST CANCER ETIOLOGY
FEBRUARY 2015
VICTORIA HART
B.S., CORNELL UNIVERSITY
M.S., UNIVERSITY OF VERMONT
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Katherine W. Reeves

Much about the etiology of breast cancer remains unknown. One of the strongest
predictors of breast cancer risk is mammographic density; however, the mechanisms relating
density to breast cancer risk are not fully understood and this has limited the use of
mammographic density as a marker for breast cancer susceptibility. Hormone fluctuations
during the menopausal transition may influence declines in mammographic density and may also
trigger the onset of menopausal vasomotor symptoms (VMS), which have been associated with
lower breast cancer risk. The effects of hormone changes on density, VMS, and ultimately breast
cancer risk are complicated by external factors such as changing body mass and exogenous
hormone therapy use during the menopausal transition.
We evaluated the longitudinal association between change in BMI and change in breast
density among 24,556 women in the Breast Cancer Surveillance Consortium using a novel
volumetric measurement method. We found that an annual increase in BMI was associated with
a decrease in both absolute dense volume (β=-1.01 cm3, 95% CI -1.59, -0.42) and in percent
dense volume (β=-1.17%, 95% CI -1.31, -1.04). Longitudinal studies of density and breast
cancer, or those using density to reflect breast cancer risk, should thus consider controlling for
BMI gain/loss to understand the independent relationship between density and risk. We further
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investigated the association of VMS and percent mammographic density (PMD) among 833
women enrolled Study of Women’s Health Across the Nation (SWAN) Mammographic Density
Sub-study. We observed no overall association between VMS and PMD (β = -0.47%, 95% CI 1.39, 0.45), although some evidence of an inverse association was found among perimenopausal
women (β = -1.29%, 95% CI -2.58, -0.001) and those using hormone therapy (β = -3.62%, 95%
CI -7.17, -0.07). These results suggest that an association between VMS and breast cancer risk is
via a pathway that is not strongly mediated by changes in breast density. Finally, we evaluated
VMS and incident breast cancer risk within the full SWAN cohort of 3,098 women. VMS were
associated with a 38% reduction in breast cancer risk (OR 0.62, 95% CI 0.39, 0.99). Adjustment
for endogenous hormone levels in this analysis did not alter our results, suggesting that
endogenous hormones may play a lesser role in the observed association between VMS and
breast cancer risk than has been previously hypothesized.
The results of these studies further our understanding of breast cancer etiology. If
confirmed, the association between VMS and breast cancer risk could propose VMS as an easily
measured factor that may be used to enhance risk prediction in clinical practice. Our findings that
this association is not strongly mediated through breast density nor endogenous hormone levels
raise provocative questions regarding the biological mechanisms that may link VMS to breast
cancer risk. Extending our knowledge of breast cancer etiology using new measurement methods
and novel risk factors may lead to improved risk prediction and provide opportunities for disease
prevention.
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CHAPTER 1
THE EFFECT OF WEIGHT CHANGE ON VOLUMETRIC MEASURES OF
MAMMOGRAPHIC DENSITY: A LONGITUDINAL STUDY IN THE BREAST
CANCER SURVEILLANCE CONSORTIUM

1.1 Abstract
The impact of changing body mass index (BMI) on breast composition is unclear. The
association between BMI and breast density is important in evaluating adjustment for BMI
gain/loss in longitudinal studies of density and breast cancer risk. In cross-sectional analysis,
BMI has been associated with lower dense breast area but higher dense breast volume. No
studies to date have explored a longitudinal association using volumetric methods to assess
density.
We examined the association between change in BMI and change in volumetric density
in a population of 24,556 women who received breast imaging at the San Francisco site of the
Breast Cancer Surveillance Consortium from 2007-2013. Height and weight were self-reported
at the time of the mammogram. Breast density was assessed using single x-ray absorptiometry
(SXA) volumetric measurement. The cross-sectional and longitudinal associations between BMI
and absolute dense volume (DV), absolute non-dense volume (NDV) and percent dense volume
(PDV) were assessed using multivariable adjusted regression.
The study population was primarily Caucasian (66%) or Asian (25%). Most women were
postmenopausal (64%) and normal weight (63%) at first mammogram. In cross-sectional
analysis, BMI was positively associated with DV (β=2.95 cm3, 95% CI 2.69, 3.21) and inversely
associated with PDV (β=-2.03%, 95% CI -2.09, -1.98). By contrast, in longitudinal analysis an
annual increase in BMI was associated with an annual decrease in both DV (β=-1.01 cm3, 95% CI
-1.59, -0.42) and PDV (β=-1.17%, 95% CI -1.31, -1.04). These findings were consistent between
pre- and postmenopausal women. Among premenopausal women, the annual decrease in DV
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was only observed among women who were initially overweight or obese (p<0.01 for interaction
by initial BMI).
Our findings support an inverse association between change in BMI and change in
percent density. Longitudinal studies of BMI or PDV and breast cancer risk should consider
adjusting for change in the other factor. The association between increasing BMI and decreasing
absolute DV is unexpected and will require confirmation using SXA and other volumetric
methods.

1.2 Introduction
Percent dense area (PDA), the ratio of dense breast tissue compared to total breast tissue
on a mammographic image, is a known risk factor for primary breast cancer (1-4). However, the
relative contributions of dense and non-dense tissue to breast cancer risk are not fully understood.
Dense tissue reflects epithelial and stromal tissue where malignant growth may initiate, and larger
amounts may provide more opportunity for abnormal cell development (5). Androstenedione is
converted to estrogen in non-dense adipose tissue, and greater estrogen exposure also has been
associated with increased risk (6). In cross-sectional analysis, higher body mass index (BMI) has
been strongly linked to higher non-dense area (NDA) and weakly linked to lower dense area
(DA) on a mammographic image (2, 7, 8). However, cross-sectional studies assessing dense
breast volume have found positive associations between BMI and both non-dense volume (NDV)
and dense volume (DV) (9-12). Several methods of assessing breast volume have been proposed
as enhancements over area assessment (11, 13-15). Single X-ray absorptiometry (SXA), which
calculates breast volume using a calibrated phantom included in the mammographic image, may
more accurately predict breast cancer risk than area methods (15). BMI and breast density may
negatively confound each other in their associations with breast cancer risk (8, 16, 17).
Understanding the impact of BMI on breast composition is necessary to determine how these
factors should be included and controlled for in studies of risk.
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Neither breast density nor BMI are static values. It is understood that PDA decreases
during aging, and that the rate of decline is greatest during the menopausal transition (18-20). A
recent study showed that PDA declined less over time for women who went on to be diagnosed
with breast cancer than for age-matched controls (21). It is unclear how changing BMI influences
the decline in density. A limited number of longitudinal studies have shown an inverse
relationship between change in BMI and change in PDA (22, 23), and have reported either a null
(22) or positive (23) association between change in BMI and change in absolute DA. To date, no
studies have evaluated the longitudinal effect of change in BMI on change in density using
volumetric methods. This relationship must be established to understand the impact of adjusting
for unstable BMI in longitudinal studies that use change in breast density to reflect breast cancer
risk.
We examined the cross-sectional and longitudinal associations between BMI and breast
density using the SXA volumetric density measurement method. Our analysis was conducted in
the Breast Cancer Surveillance Consortium, a large cohort of women undergoing breast imaging.
Based on prior cross-sectional analyses using volumetric methods (9-12), we hypothesized that an
increase in BMI over the study period would be associated with an increase in both dense volume
(DV) and non-dense volume (NDV), and a decrease in percent dense volume (PDV).

1.3 Methods
1.3.1 Study population
The Breast Cancer Surveillance Consortium (BCSC) was established by the National
Cancer Institute in 1994. At each of seven locations, screening mammography data are linked to
cancer registry information at each site then pooled across sites to provide a large sample of
women. The BCSC sites were selected to represent urban, suburban, and rural locations and a
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diverse racial/ethnic pool. As of February 2013, the full BCSC database included approximately
9.5 million mammograms and over 113,000 breast cancer cases (24).
The current study used data from the San Francisco Mammography Registry (SFMR),
one of two BCSC sites at which volumetric mammographic density has been measured since
2007. At the time of their screening mammogram, women completed a self-administered, onepage questionnaire providing basic demographic, medical, and reproductive history information.
The questionnaire allowed women to opt out of having their data included in BCSC research.
The average opt out rate for the facilities contributing to the SFMR is 1.8% (range: 0.8-3.3%).
The eligible study sample included women age 18 and older with two or more mammograms in
2007-2013 spaced at least nine months apart. Women with history of breast cancer, mastectomy,
breast implants, or breast surgery were excluded from the study sample. Mammograms that were
performed within 6 months of a breast cancer diagnosis were also excluded. The eligible sample
consisted of 30,000 women who contributed 75,489 mammograms. A total of 1,149
mammograms were excluded due to poor placement of the SXA phantom in the mammographic
image resulting in volumetric density measurement error. After this exclusion, 368 women had
only one mammogram to contribute to the analysis and were therefore also excluded. These
exclusions resulted in an eligible study population of 29,632 women and 73,972 mammograms
(average 2.54 mammograms per woman). The average time between first and last contributed
mammogram was 2.4 years (range 0.8-5.9 years).

1.3.2 BMI assessment
Women self-reported their current height in inches and weight in pounds at the time of
their screening mammogram, and these data were used to calculate BMI. Women were excluded
from the study sample if their reported height between mammograms varied by more than 3
inches (470 women, 1,197 mammograms). BMI was analyzed both in its original continuous
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form and categorized according to WHO guidelines: <18.5 kg/m2 for underweight, 18.5-<25
kg/m2 for normal weight, 25-<30 kg/m2 for overweight, and >=30 kg/m2 for obese.

1.3.3 Volumetric breast density assessment
Dense breast volume and percent dense breast volume were measured using the single xray absorptiometry (SXA) technique. A complete description of the specific SXA imaging
methods, development, and calibration processes can be found elsewhere (25, 26). Briefly, a
specialized SXA phantom was included in the x-ray field during the mammography examination
and was used to convert pixel grayscale values into unique volumes of adipose (non-dense) and
fibroglandular (dense) breast tissue for each given pixel value (26). The SXA phantom was
specifically designed to not interfere with standard screening procedures and to account for tilt of
the compression surfaces during the examination (15, 26). The mean difference in PDV
measurements between repeat readings using this technique has been demonstrated to be less than
2.5% (15).

1.3.4 Covariate assessment
Data on demographics, reproductive and menstrual history, family history, and brief
medical history were obtained via the one-page questionnaire administered at the time of the
screening mammogram. The covariates selected as potential confounders or effect modifiers for
this analysis were based on known predictors of mammographic density and availability within
the BCSC dataset. Covariates assessed at the time of the first screening mammogram and
considered unchanging included age at first mammogram, race, ever given birth, age at first birth,
education, first degree family history of breast cancer, and prior history of breast biopsy. Timevarying covariates included menopausal status, hormone therapy use, and hormonal birth control
use. Consistent with previous analyses using BCSC data, women were considered
postmenopausal if they reported that menstrual periods had stopped for more than 12 months, if
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they reported a bilateral oophorectomy, or if they reported a hysterectomy and were 55 years of
age or older. Women were otherwise considered premenopausal. Current use of hormone
therapy and hormonal birth control were assessed at the time of the screening mammogram. The
questionnaire did not include specific formulations of hormone therapy or history of prior use.

1.3.5 Statistical analysis
We additionally excluded 4,606 women (11,122 mammograms) who were missing data
on one or more covariates included in the multivariable model. There were no statistically
significant differences in the remaining covariates between women who were excluded from the
analysis and those who were retained (data not shown). The final analytic sample included
24,556 women who contributed 61,653 mammograms.
We calculated descriptive statistics for available demographic and reproductive
characteristics. We assessed the cross-sectional association between BMI at first mammogram
and volumetric density measures at first mammogram using a generalized linear regression model
adjusted for all covariates. Log transformations of density variables were used to satisfy
normality assumptions. In longitudinal analyses we calculated annual change in BMI and
volumetric density measures as (Δ value / Δ time, days) × 365.25 days/year to account for
varying time lapse between mammograms. We categorized BMI change over the study period
based on change from initial BMI (at first mammogram): ≥10% loss, 5-10% loss, stable within
±5%, 5-10% gain, and ≥10% gain. We used ANOVA to compare the percent gain/loss based on
initial BMI, using the underweight or normal range (<25 kg/m2) as the reference. We
summarized the annual change in each volumetric density measure over the study period and
calculated adjusted means and confidence intervals using generalized linear regression.
We assessed the association between annual change in BMI and annual change in DV,
NDV, and PDV using a random intercept mixed effects model. The mixed effects model is
appropriate for data in which each subject may contribute a varying number of observations, and
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the random intercept allows for individual subject variation in baseline density measures (27).
The model was adjusted for all covariates listed above and time-varying factors were updated at
each successive mammogram. We stratified all analyses by menopausal status (premenopausal,
postmenopausal, or transitioned from pre- to postmenopausal) because the association between
BMI and breast cancer risk has been shown to vary between pre- and postmenopausal women
(28, 29). Because analyses have shown that declines in PDA over the menopausal transition may
be modified by initial BMI and hormone therapy use (18, 19), we tested for effect modification
by BMI at the first mammogram and by hormone therapy (never user, consistent user, initiated
use during the study period, discontinued use during the study period).
All analyses were performed using SAS Version 9.2 (SAS Institute, Cary, North
Carolina).

1.4 Results
A majority of the study population was Caucasian (66.3%) with 25.1% Asian or Pacific
Islander (Table 1). The average age at the first mammogram was 56.4 years, and 64.1% of
women were postmenopausal. Over half of the study population was classified as normal weight
at the first mammogram (62.6%), while 24.2% were classified as overweight and 10.9% were
classified as obese. About 12% of the study population was using hormone therapy at the time of
the first mammogram.
In cross-sectional analysis, BMI at first mammogram was positively associated with both
DV (β=2.95 cm3, 95% CI 2.69, 3.21) and NDV (β=51.03 cm3, 95% CI 49.93, 52.13) at first
mammogram, and was inversely related to PDV at first mammogram (β=-2.03%, 95% CI -2.09, 1.98) (Table 2). The associations with NDV and with PDV were stronger among women who
were initially premenopausal compared to those who were initially postmenopausal (p value for
interaction by menopausal status: p=0.79 for DV, p<0.01 for NDV, p<0.01 for PDV). No
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significant interaction by hormone therapy (HT) use was observed (p value for interaction by HT
use: p=0.60 for DV, p=0.15 for NDV, p=0.81 for PDV).
A majority of women maintained stable weight within ± 5% of their initial BMI during
the study period (73.6%) (Table 3). Regardless of menopausal status, a higher proportion of
women who were initally overweight or obese lost over 5% of their initial BMI compared to
women who were initially lean (premenopausal: 6.1%, 16.4%, and 21.2% of normal, overweight,
and obese women, respectively, p<0.01; postmenopausal: 9.3%, 18.3%, and 23.9% of normal,
overweight, and obese women, respectively, p<0.01). A higher proportion of initially overweight
or obese premenopausal women gained over 5% of their initial BMI compared to initially lean
premenopausal women (13.9%, 17.6%, and 17.0% of normal, overweight, and obese women,
respectively, p = 0.01). No difference in weight gain by initial BMI was observed among
postmenopausal women (13.3%, 13.6%, 13.0% of normal, overweight, and obese women,
respectively, p=0.86).
The mean annual change in DV, NDV, and PDV over the study period was -0.56
cm3/year, 6.09 cm3/year, and -0.81 %/year, respectively (data not shown). A 1 kg/m2 annual
increase in BMI was associated with a statistically significant decrease in DV (β=-1.01 cm3, 95%
CI -1.59, -0.42), increase in NDV (β=26.2 cm3, 95% CI 23.5, 28.9), and decrease in PDV (β=1.17%, 95% CI -1.31, -1.04) in the full study population (Table 4). Results were strongest among
premenopausal women, although significant interaction by menopausal status was only observed
for NDV and PDV (p value for interaction by menopausal status: p=0.43 for DV, p=0.01 for
NDV, p<0.01 for PDV). When further stratified by initial BMI, the significant annual decrease in
DV was observed among premenopausal women who were intitally overweight or obese, but not
among premenopausal women who were initially underweight or normal BMI (p value for
interaction by initial BMI: p<0.01). Among postmenopausal women, annual decrease in DV was
not statistically significant after stratification by initial BMI and no interaction was observed (p
value for interaction by initial BMI: p=0.67). Likewise, no interaction between DV and initial
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BMI was oberved among the women who transitioned from pre- to postmenopausal (p value for
interaction by initial BMI: p=0.52). Regardless of menopausal status, the significant annual
decrease in PDV associated with an increase in BMI was strongest among initially lean women
and progressively weaker among initially overweight and obese women (p value for interaction
by intial BMI: p<0.01 for all menopausal status groups). We observed no significant overall
interaction by HT use (p value for interaction by HT use: p=0.44 for DV, p=0.15 for NDV,
p=0.40 for PDV).

1.5 Discussion
Consistent with our expectations, we observed positive cross-sectional relationships
between BMI and both DV and NDV, and an inverse cross-sectional relationship between BMI
and PDV. We also observed that DV and PDV declined on average over the study period.
However, in contrast to our expectations, we found that an annual increase in BMI was associated
with an annual decrease in DV in longitudinal analysis. This finding was consistent among preand postmenopausal women, and varied by initial BMI among premenopausal women. An
annual increase in BMI was further associated with an annual decrease in PDV among all
menopausal status groups, as a result of increases in NDV associated with increasing BMI.
Our finding of a positive cross-sectional relationship between BMI and DV is consistent
with studies using the SXA method (12) and other volumetric techniques (9, 10, 30), but in
contrast with studies using area assessment (8, 31). Unlike area methods, which rely on a
dichotomous separation of dense and non-dense area, the SXA method calculates a continuous
value for DV based on the comparison of each pixel on the mammographic image to a known
phantom (26). Continuous assessment of DV may provide a more accurate assessment of dense
tissue than dichotomous area methods. Further, the SXA method includes water in adipose tissue
in its calculation of DV (15). A recent study comparing area and SXA volume measurements
reported that correlations between DA and DV were stronger among lean women than among
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obese women as a result of this inclusion (12). The contribution of water from adipose tissue
may partially account for the positive cross-sectional association between BMI and DV.
Our observed 1.17% annual decline in PDV associated with a unit annual increase in
BMI is similar in magnitude to the two previous studies of change in BMI and PDA over time,
which reported annual declines of 0.36% (22) and 1.44% (23). However, our observation of a
decrease in DV with increasing BMI does not support their findings of no association (22) or
positive association (23) between change in BMI and DA. The association between change in
BMI and change in DA observed by Reeves et al (22) was in the same direction as our finding,
but their results among 833 women were not statistically significant. Although we observed a
significant annual decrease in DV, it should be noted that the magnitude, approximately 1
cm3/year, is small compared to the initial average DV in our study population (142.3 cm3) and
compared to the difference in DV that was associated with increased breast cancer risk in a casecontrol analysis of 864 women using SXA (women in the highest quintiles of DV (192+ cm3) had
significantly higher risk compared to those in the lowest quintile (<122.3 cm3)) (15).
We observed that the longitudinal association between BMI and DV was strongest among
premenopausal women who were initially overweight or obese. These women were more likely
to gain more than 5% of their initial weight during the study period than their lean counterparts.
It is possible that the association between change in BMI and DV was easiest to observe among
women who gained more weight, since a larger change in BMI may allow us to see the associated
small change in DV. The inverse association between BMI and DV also was observed among
postmenopausal women, but did not vary by initial BMI. Likewise, no difference in weight gain
by initial BMI was observed among postmenopausal women who were postmenopausal at
baseline. The biological mechanism linking an annual increase in BMI to an annual decrease in
absolute DV is unclear. Like other volumetric methods, the SXA technique calculates breast
volume based on the two-dimensional mammographic image. It is possible that our finding may
reflect differences in capturing dense breast tissue on a mammographic image for large- versus
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small-breasted women as opposed to a true reduction in DV with increasing BMI. Future studies
using SXA and other volumetric measurement techniques are necessary to confirm our results.
Joint cross-sectional analyses of BMI and PDA and breast cancer risk suggest that these
are independent breast cancer risk factors in both pre- and postmenopausal women (8, 17, 32),
and that the association of either factor with breast cancer risk is strengthened after adjustment for
the other factor (8, 32). Therefore studies of either factor should control for the other to avoid
negative confounding. The significant associations that we observed between change in BMI and
change in density measures suggest that longitudinal studies of volumetric density and breast
cancer risk should additionally consider adjusting for change in BMI (i.e. weight gain or loss) to
fully understand the independent effect of change in volumetric density on breast cancer risk.
Further, longitudinal studies using change in density outcomes as an indicator of changing breast
cancer risk should carefully evaluate the potential for confouding by gain or loss in BMI and also
consider adjustment as necessary.
Our study is strengthened by the large number of participants and by the fact that height
and weight were reported at the time of the screening mammogram. In addition, volumetric
density was assessed using a validated method that has been found to more accurately predict
breast cancer risk than area assessment (15). Our results must be interpreted in context of the
study limitations, however. First, height and weight were self-reported. Validity of self-reported
height and weight measures has been assessed within a subset of the BCSC cohort (12) and the
Spearman correlation coefficient between BMI from self-reported and measured values was 0.949
(95% CI 0.938, 0.957). Second, our ability to adjust for confounding variables is limited by the
information collected on the BCSC questionnaire. The questionnaire was designed to minimize
burden on women at their routine screening mammogram and therefore includes fewer questions
than might be asked during a targeted research study. We have adjusted for confounding to the
extent possible, but residual confounding by other factors related to BMI and breast density may
exist. Lastly, our study sample was primarily Caucasian and Asian women. Both
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mammographic density (33, 34) and body composition (28) have been shown to vary by
racial/ethnic group, meaning that our findings may not be generalizable to a more diverse
population.
The independent and collective roles of BMI and breast density in breast carcinogenesis
are unclear and are complicated by the dynamic nature of both body and breast composition over
time. This analysis supports the current understanding that an increase in BMI is associated with
a decrease in percent density and suggests that change in PDV over time may differ based on
starting BMI. Our unexpected finding of a decrease in DV with increasing BMI is contrary to our
current understanding of the mechanisms relating dense breast tissue, BMI, and breast cancer
risk. Confirmation using other volumetric techniques is required to ensure that our finding is not
the result of chance or an artifact of our measurement method.
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Table 1: Selected patient characteristics measured at first mammogram
(N=24,556); BCSC SFMR 2007-2013

Study population
N (%)
General characteristics
Age at mammogram (years); Mean (SD)

56.4 (10.9)

2

BMI (kg/m ); Mean (SD)
Underweight: <18.5
Normal weight: 18.5 - <25
Overweight: 25 - <30
Obese: 30+
Race
Caucasian
African-American
Asian / Pacific Islander
Other
Education level
< High school
High school diploma
Some college
College degree
First degree family history of breast cancer
Previous breast biopsy
Reproductive history
Menopausal status
Premenopausal
Postmenopausal
Ever given birth
Age at first birth
Nulliparous
< 20 years
20 - 29 years
30 - 39 years
40+ years
Hormone therapy use (at first mammogram)
Birth control hormone use (at first mammogram)
Tamoxifen or raloxifene use (at first mammogram)

24.5 (4.6)
583 (2.4)
15,363 (62.6)
5,938 (24.2)
2,672 (10.9)
16,268 (66.3)
519 (2.1)
6,184 (25.2)
1,585 (6.4)
747 (3.0)
1,820 (7.4)
4,970 (20.2)
17,019 (69.3)
4,787 (19.5)
5,785 (23.6)

8,355 (34.0)
15,734 (64.1)
16,315 (66.4)
8,183 (33.3)
835 (3.4)
7,681 (31.3)
7,031 (28.6)
826 (3.4)
3,001 (12.2)
1,493 (6.1)
204 (< 1.0)

Percentages may not add to 100% due to unknown values (<10% for any
characteristic)
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Table 2: Cross-sectional association between BMI and volumetric density measures at first mammogram; BCSC SFMR
2007-2013

N
(women)
All women

Mean (SD) at first
mammogram

β (SE) a

95% CI

P value

142.3 (76.7)

2.95 (0.13)

2.69, 3.21

<0.001

416.8 (331.0)
32.5 (19.5)

51.03 (0.56)
-2.03 (0.03)

49.93, 52.13
-2.09, -1.98

<0.001
<0.001

166.7 (83.7)

3.05 (0.27)

2.51, 3.58

< 0.001

327.1 (303.2)
42.3 (21.3)

53.64 (0.98)
-2.88 (0.06)

51.72, 55.55
-3.00, -2.77

< 0.001
< 0.001

129.1 (69.1)

2.97 (0.16)

2.67, 3.28

< 0.001

465.6 (336.2)
27.3 (16.2)

49.96 (0.69)
-1.67 (0.03)

48.61, 51.31
-1.73, -1.61

< 0.001
< 0.001

24,556

Dense breast volume (cm3)
3

Non-dense breast volume (cm )
Percent dense breast volume (%)
Premenopausal at first mammogram

8,355

3

Dense breast volume (cm )
Non-dense breast volume (cm3)
Percent dense breast volume (%)
Postmenopausal at first mammogram
Dense breast volume (cm3)
3

Non-dense breast volume (cm )
Percent dense breast volume (%)

15,734

a

Adjusted for age at first mammogram, race, education, first degree family history of breast cancer, history of breast biopsy,
ever given birth (yes/no), menopausal status at first mammogram (all women), and hormone use at first mammogram
Stratified results exclude 467 women with unknown menopausal status at first mammogram

Table 3: Change in BMI from first mammogram to last mammogram, stratified by menopausal status and by BMI at first mammogram
(kg/m2); BCSC SFMR 2007-2013
N
(women)
All women

24,556

> 10% loss
N (%)

5-10% loss
N (%)

Stable ± 5%
N (%)

5-10% gain
N (%)

> 10% gain
N (%)

839 (3.4)

2,177 (8.9)

18,059 (73.6)

2,584 (10.5)

897 (3.6)

Premenopausal (all exams)
7,266
Underweight or normal: <25
5,203
45 (0.9)
271 (5.2)
4,163 (80.0)
558 (10.7)
Overweight: 25 - <30
1,487
71 (4.8)
172 (11.6)
983 (66.0)
185 (12.4)
Obese: 30+
576
57 (9.9)
65 (11.3)
356 (61.8)
78 (13.5)
Postmenopausal (all exams)
15,715
Underweight or normal: <25
9,682
168 (1.7)
735 (7.6)
7,489 (77.4)
956 (9.9)
Overweight: 25 - <30
4,093
239 (5.8)
513 (12.5)
2,787 (68.1)
417 (10.2)
Obese: 30+
1,940
191 (9.9)
272 (14.0)
1,224 (63.1)
181 (9.3)
Transition from pre- to postmenopausal
1,089
Underweight or normal: <25
728
14 (1.9)
57 (7.8)
519 (71.3)
100 (13.7)
Overweight: 25 - <30
260
17 (6.5)
27 (10.4)
166 (63.9)
33 (12.7)
Obese: 30+
101
12 (11.9)
14 (13.9)
59 (58.4)
9 (8.9)
Stratified results exclude observations for 486 women with unknown menopausal status at one or more mammogram(s)

166 (3.2)
78 (5.2)
20 (3.5)
331 (3.4)
137 (3.4)
72 (3.7)
38 (5.2)
17 (6.5)
7 (6.9)

Table 4: Association between annual change in BMI and annual change in volumetric density measures, stratified by menopausal status
and by BMI at first mammogram (kg/m2); BCSC SFMR 2007-2013

All women
Premenopausal (all exams)
Underweight or normal: <25
Overweight: 25 - <30
Obese: 30+
Postmenopausal (all exams)
Underweight or normal: <25
Overweight: 25 - <30
Obese: 30+
Transition from pre- to postmenopausal
Underweight or normal: <25
Overweight: 25 - <30
Obese: 30+
a

N
(women)
24,556
7,266
5,203
1,487
576
15,715
9,682
4,093
1,940
1,089
728
260
101

Annual change in dense breast volume Annual change in non-dense breast volume Annual change in percent dense breast volume
(cm3 per year)
(cm3 per year)
(% per year)
a
95% CI
p value
95% CI
p value
95% CI
p value
β (SE)
β (SE) a
β (SE) a
-1.01 (0.30)
-1.59, -0.42
0.001
26.2 (1.38)
23.45, 28.87
< 0.001
-1.17 (0.07)
-1.31, -1.04
< 0.001
-1.73 (0.73)
-3.17, -0.30
0.02
32.64 (2.63)
27.47, 37.80
< 0.001
-1.83 (0.14)
-2.10, -1.56
< 0.001
0.92 (0.74)
-0.52, 2.37
0.21
31.17 (2.65)
25.97, 36.37
< 0.001
-2.84 (0.23)
-3.30, -2.38
< 0.001
-2.71 (0.98)
-4.63, -0.80
0.01
33.56 (4.50)
24.74, 42.37
< 0.001
-1.47 (0.21)
-1.87, -1.07
< 0.001
-3.29 (1.90)
-7.01, 0.44
0.08
32.63 (6.48)
19.93, 45.32
< 0.001
-0.86 (0.17)
-1.18, -0.53
< 0.001
-0.74 (0.32)
-1.36, -0.12
0.02
24.08 (1.63)
20.89, 27.27
< 0.001
-0.95 (0.08)
-1.10, -0.80
< 0.001
-0.32 (0.32)
-0.95, 0.31
0.32
22.93 (2.95)
17.15, 28.70
< 0.001
-1.51 (0.20)
-1.91, -1.11
< 0.001
-0.94 (0.66)
-2.23, 0.36
0.16
31.09 (1.73)
27.70, 34.47
< 0.001
-1.08 (0.11)
-1.29, -0.87
< 0.001
-0.53 (0.61)
-1.73, 0.67
0.39
20.57 (2.56)
15.55, 25.58
< 0.001
-0.35 (0.09)
-0.52, -0.17
< 0.001
-1.40 (1.85)
-5.02, 2.23
0.45
24.20 (5.15)
14.11, 34.29
< 0.001
-1.48 (0.27)
-2.02, -0.94
< 0.001
-0.62 (1.22)
-3.02, 1.78
0.61
33.24 (4.76)
23.91, 42.58
< 0.001
-2.89 (0.43)
-3.73, -2.05
< 0.001
-2.81 (1.30)
-5.36, -0.27
0.03
22.80 (9.92)
3.35, 42.25
0.02
-1.25 (0.49)
-2.21, -0.29
0.01
0.21 (4.70)
-9.00, 9.43
0.96
17.94 (8.42)
1.44, 34.44
0.03
-0.35 (0.33)
-0.99, 0.29
0.28

Adjusted for age at first mammogram, age at first birth, history of breast biopsy, education, ever given birth (yes/no), first degree family history of breast cancer, hormone use during study period, menopausal
status (all women), and race
Stratified results exclude observations for 486 women with unknown menopausal status at one or more mammogram(s)
P value for interaction by menopausal status: DV p=0.43, NDV p=0.01, PDV p<0.01
P value for interaction by BMI at first mammogram:
premenopausal women: DV p<0.01, NDV p=0.87, PDV p<0.01
postmenopausal women: DV p=0.67, NDV p<0.01, PDV p<0.01
transitioning women: DV p=0.52, NDV p=0.24, PDV p<0.01

CHAPTER 2
MENOPAUSAL VASOMOTOR SYMPTOMS AND MAMMOGRAPHIC DENSITY IN
THE STUDY OF WOMEN’S HEALTH ACROSS THE NATION

2.1 Abstract
Declines in endogenous estrogen during menopause have been independently linked to
the onset of menopausal vasomotor symptoms (VMS) and to reduced breast cancer risk. Percent
mammographic density (PMD) is viewed as a marker for breast cancer susceptibility. A
relationship between VMS and PMD may improve understanding of breast cancer etiology and
justify future investigations of VMS and breast cancer risk.
We investigated this association among 833 women enrolled in the Study of Women’s
Health Across the Nation (SWAN) Mammgraphic Density Substudy. Women were pre- or
perimenopausal at enrollment and followed for six annual visits. VMS were self-reported at
annual SWAN visits. PMD was ascertained from routine screening mammograms. A linear
mixed effects model was used to evaluate the longitudinal association between VMS and PMD.
Women contributed a total of 4,748 mammograms (2-10 per woman) over a median 5.4
years of follow-up. We observed no overall association between VMS and PMD. Among
perimenopausal women, VMS was associated with significantly lower PMD (β = -1.29%, 95% CI
-2.58, -0.001). Similar results were observed among those with unknown menopausal status due
to hormone use during follow-up (β = -3.62%, 95% CI -7.17, -0.07). Among women who
transitioned to postmenopause without surgery, VMS was not associated with change in PMD
across the menopausal transition.
Although our findings do not demonstrate a consistent relationship between VMS and
PMD, we did observe an association among perimenopausal women and those using hormone
therapy during the menopausal transition. Further prospective studies are needed to determine the
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extent to which an observed decrease in breast cancer risk among women with VMS may be
mediated by PMD.

2.2 Introduction
Menopausal vasomotor symptoms (VMS), which include hot flashes and night sweats,
are frequently reported by women during menopause, occurring in up to 75% of women during
and after the menopausal transition (35-38). Two recent case-control studies (39, 40) and one
prospective study (Hart, in preparation) observed a 40-50% reduction in breast cancer risk among
women who experienced VMS at any point during the menopausal transition compared to those
who did not.
The mechanism that triggers the onset of VMS in symptomatic women may be related to
a mechanism responsible for lower breast cancer susceptibility. Higher levels of endogenous
estrogens have been positively associated with postmenopausal breast cancer risk (41); whereas
the fluctuation and eventual decline in estrogen levels prior to menopause appears to be related to
VMS onset. Previous work demonstrates that estrogen fluctuations may be responsible for a
narrowing of the thermoneutral range (42), for a lack of responsiveness to thermal changes at the
skin vasculature (43), and for changes in the regulation of central nervous system chemicals that
trigger thermoregulatory response (44, 45). Hormone therapy (HT) has been shown to be a
consistently effective treatment for VMS (46), indicating that the regulation of estrogen levels is
important to the management of symptoms. However, non-hormonal treatments also have been
shown to relieve VMS (47, 48), suggesting that VMS may be triggered by factors other than
fluctuating hormone levels.
Percent mammographic density (PMD), the proportion of dense epithelial and connective
breast tissue compared to total breast tissue on a mammographic image (2), has been consistently
demonstrated as a strong risk factor for breast cancer (49), and high PMD is viewed as a marker
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of breast cancer susceptibility (50). The role of menopausal hormone fluctuations on PMD is
unclear, although studies have shown consistent declines in PMD and dense breast area with age
and across the menopausal transition (18, 19, 51). Investigations also have found positive
associations between PMD and circulating estradiol (52, 53). Declines in PMD during
menopause appear to be modified by HT use, further suggesting hormonal influences on changes
in breast tissue (18, 19). Common hormonal mechanisms affecting VMS and PMD provide
justification for examining the relationship between these factors, and have the potential to
provide prospective information regarding VMS and future breast cancer risk among healthy
women.
We evaluated the association of VMS with PMD in the Study of Women’s Health Across
the Nation (SWAN), a large prospective cohort of women transitioning through menopause. We
anticipated that VMS would be associated with lower PMD and indicative of a lower
susceptibility to breast cancer. Specifically, we hypothesized that VMS would be inversely
associated with PMD, overall and within each menopausal stage. We additionally hypothesized
that women who experienced VMS while pre- or perimenopausal would have a greater decline in
PMD across the menopausal transition compared to women who did not experience VMS while
pre- or perimenopausal.

2.3 Methods
2.3.1 Study population
The Study of Women’s Health Across the Nation (SWAN) was designed to characterize
biological and psychosocial changes over the menopausal transition in a multiracial/ethnic cohort.
A detailed description of the SWAN design and recruitment procedures is provided elsewhere
(54). Briefly, each of seven SWAN sites recruited women starting in 1996, with certain locations
oversampling from specific racial/ethnic groups to create a diverse cohort. Baseline eligibility
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criteria for SWAN enrollment included being aged 42-52 years, having an intact uterus and at
least one ovary, not being pregnant or lactating, not using oral contraceptives or hormone therapy,
and having a menstrual cycle in the three months before enrollment. A total of 3,302 women
were enrolled, and each participant provided written informed consent at the location of
enrollment. Baseline clinical assessments were performed in 1996-1997 and annual follow-up
assessments are on-going.
The current study involved SWAN participants enrolled in the ancillary Mammographic
Density Sub-study. This sub-study was designed to examine factors related to mammographic
density and changes in mammographic density over the course of the menopausal transition.
Women at three SWAN sites were enrolled in the sub-study during follow-up visit 05 or 06
(N=1,055), representing four racial/ethnic groups. African-American women were enrolled from
the Pittsburgh, PA site, Chinese women from the Oakland, CA site, and Japanese women from
the Los Angeles, CA site. Caucasian women were enrolled from all three locations. Separate
written informed consent was obtained from these women to obtain prior mammograms taken at
routine screenings up to two years prior to the baseline SWAN visit through two years after
follow-up visit 06. Women with a previous breast surgery in both breasts (i.e., breast
augmentation, reduction or reconstruction) were not eligible for the Mammographic Density Substudy. At least one mammogram was obtained from 95.5% of the eligible sub-study sample
(N=1,007).
The current study excluded six women with a history of breast cancer at SWAN
enrollment. A further 21 women were diagnosed with breast cancer during the follow-up period
and were censored at the time of their diagnosis; however, ten of these women had no
mammograms available prior to diagnosis and were therefore excluded completely. The outcome
of the current study was change in PMD across the menopausal transition; therefore, the 139
women with only one eligible mammogram were excluded, leaving 852 participants in the study

20

population. Three women reported being pregnant or breastfeeding during the follow-up period,
and information from these specific visits also was excluded.

2.3.2 Vasomotor symptom assessment
At the baseline and each follow-up visit, SWAN participants completed a selfadministered questionnaire that included questions related to hot flashes and night sweats. The
questions were worded as follows: “Thinking back over the last two weeks, how often have you
had hot flashes or flushes / night sweats?” Response categories were: not at all, 1-5 days, 6-8
days, 9-13 days, every day. Consistent with previous analyses in the SWAN cohort (55-57),
women who reported any hot flashes or night sweats (versus not at all) were classified as having
VMS at that visit. Women who reported having hot flashes or night sweats on 6 or more days in
the last two weeks were classified as having frequent VMS at that visit (38), while women who
reported having hot flashes or night sweats 1-5 days in the last two weeks were classified as
having infrequent VMS at that visit.

2.3.3 Mammographic density assessment
Mammographic density assessments for the obtained mammograms were performed by a
single expert reader using a compensating polar planimeter (LASICO, Los Angeles, CA) to
measure total breast area and dense breast area in cm2 on the craniocaudal view of the right
breast. Mammograms from the left breast were used for density assessment when a woman
reported biopsy or other surgery in the right breast or when films from the right breast were
unavailable. Percent density was calculated by dividing the area of dense breast tissue by the
total area of the breast. A blinded random sample of mammogram films was sent to the reader
for re-review to assess the reproducibility of the density assessments. The initial and repeat
readings resulted in a within-person Spearman correlation coefficient of 0.96 and a mean
difference in percent density assessment of 2.2% (22, 58).
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Because mammograms were retrospectively collected from routine screening visits,
mammogram dates did not typically coincide with SWAN visit dates. As a result, a difference of
several months may have existed between the collection of VMS and covariate information and
mammographic density assessment. We addressed this issue by matching each mammogram date
to the closest SWAN visit date (before or after the mammogram) for mammograms that occurred
within 90 days of a SWAN visit date (48.6% of eligible mammograms). For the remaining
mammograms, we used a novel interpolation method to estimate mammographic density at the
time of the SWAN visit dates using linear interpolation with multiple imputation to account for
error in the estimation. This method was developed by Reeves et al for the study of changes in
anthropometry with respect to mammographic density in SWAN and may provide more accurate
estimations of mammographic density at the time of the SWAN visit by accounting for the lack of
concordance between the timing of the mammogram and the timing of the SWAN visit. Details
and validation of this method are provided elsewhere (22, 59).

2.3.4 Covariate assessment
Information on covariates was collected during annual SWAN follow-up visits as part of
the clinical assessment or by interviewer- or self-administered questionnaires. The covariates
selected as potential confounders or effect modifiers for this analysis were consistent with
previous investigations of mammographic density in the SWAN cohort (22, 58, 60, 61). The
following covariates were measured at baseline and considered unchanging: race/ethnicity, age at
first birth, age at menarche, education, alcohol intake, smoking, and SWAN site. The following
additional covariates were considered time-varying and updated at each follow-up visit:
menopausal status, body mass index (BMI), parity, family history of breast cancer, hormone
therapy (HT) use, and oral contraceptive (OC) use. We considered both active and passive
exposure to smoking in our analysis, because previous investigations in the SWAN cohort have
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observed differences in these exposures with respect to both VMS and PMD (38, 62). Consistent
with the analysis of smoking and PMD by Butler et al (62), we categorized our smoking variable
as: never smoked/no passive exposure, never smoked/with passive exposure, former smoker,
current smoker.
Prior HT use was assessed during the baseline interview. By study design, women were
not currently using HT at study enrollment but could initiate HT use during follow-up. Past year
HT use was assessed at each annual follow-up interview. Women were asked to separately report
the use of estrogen, progestin, and estrogen/progestin combination therapies and formulations
were confirmed when possible using container labels. Menopausal status was classified in
accordance with SWAN protocol (54): women with no change in menstrual regularity over the
past year were considered premenopausal; women with decreased menstrual regularity in the past
three months were considered early perimenopausal; women with no menstrual bleeding in the 311 months before the interview date were considered late perimenopausal; and those with no
bleeding in the last 12 months were considered postmenopausal. Early and late perimenopause
were collapsed into a single perimenopause category for this analysis. Women who reported
bleeding in the previous 12 months and reported HT use in the previous year were reclassified as
unknown menopausal status due to HT use for those visits. Postmenopausal women remained
classified as such, regardless of HT use initiated after the final menstrual period. Women
reporting a hysterectomy or bilateral oophorectomy were classified as surgically postmenopausal
starting at the visit at which the surgery was reported.

2.3.5 Statistical methods
After applying the matching and interpolation methods described above, 19 women no
longer had two eligible mammograms matched to SWAN visits and were therefore excluded from
the study, leaving a total of 833 women. We calculated descriptive statistics for demographic and
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reproductive characteristics of the study sample and summarized VMS experience in the
population during the study period overall and by menopausal status.
Association of VMS with PMD: We used a linear mixed effects model to assess the
longitudinal association between VMS and PMD across the study period while accommodating
varying numbers of observations per woman and within-woman correlation. We included a
random intercept term to account for differing baseline PMD values. We evaluated a random
slope term to account additionally for differing changes in PMD over the study period; however,
this term did not significantly enhance the model fit, so we performed the analysis using the
simpler model. The multivariable model was developed using methods of best selection. We
assessed the univariable associations between each covariate and the exposure and outcome to
identify potential confounders. Confounders were retained in the multivariable model if they
were statistically significant (p<0.05) in the model or if their removal resulted in a change in the
regression coefficient for the VMS exposure of 10% or more.
To differentiate between symptomatic and non-symptomatic women, we modeled VMS
at each study visit as VMS reported at that visit or any prior visit. Therefore, a woman reporting
VMS at a study visit was considered symptomatic from that visit forward. This strategy was
replicated for frequent VMS (i.e., a woman reporting frequent VMS at a study visit was
considered symptomatic of frequent VMS from that visit forward). HT use was modeled
similarly to comprehensively capture use of exogenous hormones during the study period.
Because BMI is strongly associated with both VMS (38) and PMD (33), we created separate
models with and without adjustment for BMI. We assessed interactions with VMS by
race/ethnicity, HT use, and menopausal status using cross-product terms and where statistically
significant interactions were observed, we stratified the results by levels of the interaction
variable. Because hysterectomy and/or bilateral oophorectomy may be related to VMS (37), we
repeated our analyses in the subset of women who had not undergone either of these procedures.
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VMS and change in PMD: To assess the change in PMD over study period, we created
an outcome variable to represent the difference between the earliest and latest PMD observation
for each woman and an additional variable to quantify the time difference between these
observations. We used linear regression to determine adjusted mean change in PMD over the
study period and to test for differences by VMS experience, adjusting for the time difference in
our analysis. This analysis was restricted to women who non-surgically transitioned from pre- or
early perimenopausal to postmenopausal during the study period (N=426).
All analyses were performed using SAS Version 9.2 (SAS Institute, Cary, North
Carolina).

2.4 Results
The 833 women included in the study population contributed a total of 4,748
mammograms (median 4, range 2-10 mammograms per woman). The average time between
mammograms was a median of 469 days (interquartile range 385-728 days). On average, women
were 47 years old at SWAN enrollment and were premenopausal (58%) (Table 5). A majority of
the study population was Caucasian (49%) or Asian (44%), and most reported having a college
education (54%). Overall, 51% of women reported any VMS during at least one SWAN study
visit. This varied by menopausal stage, with 28%, 58% and 46% of women reporting having ever
experienced symptoms while pre-, peri-, or postmenopausal, respectively.
Association of VMS with PMD: In the full study sample, no significant difference in
PMD was observed between symptomatic and non-symptomatic women after adjustment for
covariates including BMI (β = -0.47%, 95% CI -1.39, 0.45) (Table 6). Among women who
reported HT use during the study period, results suggested an inverse relationship between VMS
and PMD (β = -3.02%, 95% CI -5.59, -0.52), although this association was attenuated and not
statistically significant after adjustment for BMI (β = -2.31%, 95% CI -4.83, 0.21) (Table 6).
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No interaction was observed between VMS and race/ethnicity (p=0.19); however, a
significant interaction was observed by menopausal status (p<0.01). During perimenopausal
visits, symptomatic women had significantly lower PMD than non-symptomatic perimenopausal
women, even following adjustment for BMI (β = -1.29%, 95% CI -2.58, -0.001) (Figure 1). This
finding was stronger among women who experienced frequent VMS, although the confidence
interval was wider and non-significant (β = -2.13%, 95% CI -4.39, 0.24). A similar, significant
relationship was observed among women with unknown menopausal status due to HT use (β = 3.62%, 95% CI -7.17, -0.07) and was again strongest in women who were symptomatic of
frequent VMS (β = -6.07%, 95% CI -11.4, -0.77). When grouped by type of HT use, the
relationship was evident among women of unknown menopausal status using progestin or
estrogen/progestin combination HT (β = -4.61%, 95% CI -8.38, -0.84), but not among similar
women using estrogen only HT (β = 3.09%, 95% CI -9.23, -15.4) (Figure 1). Results were
similar when the 54 women who reported a hysterectomy and/or bilateral oophorectomy during
the study period were excluded from the analyses (data not shown).
VMS and change in PMD: A total of 426 women fully transitioned from pre- or
perimenopause to postmenopause during the study period without a surgically induced
menopause. Compared to women who did not transition to postmenopause during the study
period, these women were slightly older (average age at enrollment 47.7 years compared to 45.2
years), reported fewer perimenopausal visits (average 3.4 visits compared to 4.9 visits), were
more likely to report VMS during perimenopausal visits (50.4% of visits compared to 45.8% of
visits), and were more likely to use HT during the study period (48% compared to 39%).
Average age at menopause for these women was 52.7 years.
Although not statistically significant, symptomatic women had slightly higher starting
and ending PMD than non-symptomatic women (starting PMD: average 43.5% compared to
42.0%; ending PMD: average 37.3% compared to 35.7%) (Table 7). No significant difference
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was observed between symptomatic and non-symptomatic women in the change in PMD across
the menopausal transition. The adjusted mean decrease in PMD was 5.3% for symptomatic
women compared to an adjusted mean decrease of 5.4% for non-symptomatic women (p=0.97)
(Table 7).

2.5 Discussion
In this racially/ethnically diverse prospective cohort, we observed no association between
VMS and PMD in the overall study population or among premenopausal or postmenopausal
women. Lower PMD was observed among women who were symptomatic for VMS in both the
perimenopausal group and the group with unknown menopausal status due to HT use, which
likely includes primarily women who are truly perimenopausal. Among women who transitioned
to postmenopause without surgery during the study period, we observed no significant difference
in the decline in PMD over the menopausal transition for symptomatic compared to nonsymptomatic women.
Two case-control studies reported significantly lower breast cancer risk among women
who experienced VMS during the menopausal transition compared to those who did not (39, 40).
However, results from prospective studies have been mixed. No association was observed in a
large prospective cohort with 13.7 years of follow-up and VMS assessment at three year intervals
(63), but a significant 38% reduction in breast cancer risk was observed in a prospective
investigation within the full SWAN cohort with 11.4 years of follow-up and annual VMS
assessment (Hart, in preparation). The mechanisms linking VMS to breast cancer risk are not
well understood, and PMD may offer one pathway through which this association may be
observed. However, the biological connection between VMS and PMD, and ultimately breast
cancer risk, is complex and may be influenced by numerous factors. Fluctuating estrogen levels
during menopause may disrupt the thermoregulatory system that triggers VMS (42). However,
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all women experience estrogen decline during menopause but not all women experience VMS,
indicating that estrogen withdrawal alone cannot account for VMS onset. Significant associations
have been observed between PMD and circulating estradiol (52, 53), but these findings are
inconsistent (64-67); and two investigations of the combined effects of circulating estradiol and
PMD concluded that hormone levels and PMD are independent risk factors for breast cancer and
only weakly related to each other (68, 69). These associations are further complicated by HT use
and BMI, which are each independently associated with VMS (38, 46), PMD (33, 70-72), and
breast cancer risk (6, 41, 73). We have carefullly adjusted for these factors in our analyses, and
our overall null results suggest that the previously reported breast cancer risk reduction among
women symptomatic for VMS is not likely mediated through observable effects of these factors
on PMD.
Although we did not observe an overall relationship between VMS and PMD, an
association was found among perimenopausal women, when VMS are typically the most
prevalent (35, 74), and among women with unknown menopausal status due to HT use, which is
often prescribed for the management of menopausal symptoms (46). Thus our findings suggest
that VMS may be associated with PMD while women are experiencing the most frequent or
intense VMS. Use of progestin or estrogen/progestin combination HT has been shown to be
associated with higher PMD (70-72). The significant association between VMS and lower PMD
among women using HT, and particularly progestin or combination HT (Figure 1), may be
observable because higher initial PMD makes it easier to witness a reduction in PMD; however,
future investigation would be required to substantiate this hypothesis. The magnitude of the
change in PMD associated with VMS in our study (4.6%) is similar to the decrease in PMD for
parous versus nonparous women (approximately 2% per pregnancy (75)), but smaller than the
typical decline in PMD for all women over the menopausal transition (mean 7.7%, 95% CI 1.914.4% (18)). Significant associations were not observed among postmenopausal women in our
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study, regardless of HT use (Figure 1). These results may be partially explained by a lack of
statistical power in these subgroups or by our definition of VMS, which classified a woman as
symptomatic from the point at which VMS were first reported. If the effect of VMS on PMD was
only evident during the time at which VMS were experienced, this definition of VMS could have
contributed to the observed attenuation of results among postmenopausal women.
To our knowledge, no previous study has investigated the change in PMD in women
undergoing the menopausal transition in relation to their VMS experience. Consistent with
previous investigations (18, 19, 76), PMD declined on average over follow-up for our study
sample; however, we observed no difference in the change in PMD for symptomatic versus nonsymptomatic women. Our findings of significantly lower PMD among symptomatic women
during perimenopause, when VMS may be most frequent or intense, suggest that differences in
the rate of change in PMD may be restricted to the perimenopause phase of the menopausal
transition. However, secondary analysis of the change in PMD across only perimenopausal visits
did not show evidence of a difference by VMS experience (data not shown). These results
support our assertion that the observed associations between VMS and breast cancer risk may act
through a mechanism that is not strongly related to PMD.
Strengths of this study include the large, population-based cohort. In addition,
menopausal status and hormone therapy use were carefully defined and monitored in SWAN,
allowing us to stratify and examine associations within specific subgroups. Further,
mammographic density was assessed by a single expert reader with high reliability. Our study
also includes some limitations. First, the mammograms used for PMD assessment were not taken
at the time of the annual SWAN visits at which VMS were assessed. Although considerable
effort was made to minimize the effect of this time difference via matching and interpolation,
some inaccuracy may have been introduced into our analysis. This inaccuracy was unlikely to be
differential by VMS experience, meaning that our results would be attenuated and less significant
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than we would have otherwise observed. Second, VMS experience was assessed at each annual
SWAN visit, at which participants were asked to report their VMS experience over the past two
weeks. Because the menopausal transition is a period of dynamic changes and symptoms may
vary over the course of a year, this assessment may have failed to completely capture VMS. In
addition, our description of VMS frequency based on number of symptomatic days in the past
two weeks does not capture VMS severity, which may vary based on intensity and number of
episodes per day. However, our VMS assessment was more comprehensive than that performed
in the previous longitudinal evaluation of VMS and incident breast cancer risk. Previous analysis
has shown that self-report of VMS differs significantly by racial/ethnic group (77, 78), and Asian
women in particular are less likely to report VMS than Caucasian or African American women
(79). Our study sample was approximately 44% Asian. Although we observed no evidence of an
interaction by race/ethnicity, our findings may not be generalizable to populations of women with
a considerably different racial/ethnic mix. Finally, because of multiple stratified analyses, we
cannot rule out the possibility that our findings may be due to chance.
In summary, this is the first study of which we are aware to examine the relation of
menopausal VMS to PMD. Findings from case-control and prospective studies of a 40-50%
reduction in breast cancer risk associated with VMS have substantial public health implications,
including the potential use of VMS as an easily measurable addition to current breast cancer risk
prediction models. Our findings of no overall association between VMS and PMD indicate that
PMD is unlikely to mediate the observed associations between VMS and breast cancer risk.
However, understanding the mechanism that does link VMS to breast carcinogenesis is critical to
realizing the impact of VMS as a possible marker of risk. This study provides evidence that
severe VMS may affect PMD while symptoms are present. Further research is necessary to
confirm these findings and evaluate the extent to which they are informative in explaining the
observed association between VMS and breast cancer risk.
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Table 5: Selected patient characteristics measured at baseline (N=833);
SWAN Mammographic Density Study
Study population
N (%)
General characteristics
Age, years: mean (SD)

46.5 (2.68)

2

BMI, kg/m : mean (SD)
25.4 (5.87)
Underweight/normal: < 25
491 (58.9)
Overweight: 25 - <30
203 (24.4)
Obese: 30+
131 (15.7)
Race
Caucasian
406 (48.7)
African-American
62 (7.4)
Asian
365 (43.9)
Education level
< High school
136 (16.3)
High school or some college
250 (30.0)
College graduate
222 (26.7)
Post-college
225 (27.0)
Family history of breast cancer (mother or sister)
74 (8.9)
Previous breast biopsy
104 (12.5)
Reproductive history
Menopausal status at baseline
Premenopausal
482 (57.9)
Early perimenopausal
346 (41.5)
Age at menarche (years)
< 12
171 (20.5)
12
234 (28.1)
13
251 (30.1)
14+
173 (20.8)
Age at first birth (years)
No children
148 (17.8)
< 20
55 (6.6)
20 - 29
395 (47.4)
30+
234 (28.1)
Number of live births
0
147 (17.6)
1
139 (16.7)
2
354 (42.5)
3+
192 (23.1)
Hormone therapy use before baseline (ever)
110 (13.2)
Oral contraceptive use before baseline (ever)
604 (72.5)
Percentages may not add to 100% due to unknown values (< 3% for any
characteristic)
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Table 6: Regression coefficients and 95% confidence intervals (CI) for percent mammographic density in relation to the presence and
frequency of self-reported VMS; SWAN Mammography Density Study

Model 1 a
95% CI

Model 2 b
95% CI

N
(mammograms)

β

All women (N=833)
Non-symptomatic (no VMS)
Symptomatic (any VMS)
Infrequent (1-5 times in past two weeks)
Frequent (6+ times in past two weeks)

4,746
1,632
3,114
2,410
704

Ref
-0.69
-0.60
-0.97

Ref
-1.61, 0.23
-1.61, 0.41
-2.56, 0.63

Ref
-0.47
-0.47
-0.47

Ref
-1.39, 0.45
-1.47, 0.53
-2.05, 1.12

HT use during study period (N=250)
Non-symptomatic (no VMS)
Symptomatic (any VMS)
Infrequent (1-5 times in past two weeks)
Frequent (6+ times in past two weeks)

1,203
222
981
692
289

Ref
-3.02
-2.71
-3.88

Ref
-5.59, -0.52
-5.47, 0.04
-7.53, -0.23

Ref
-2.31
-2.21
-2.59

Ref
-4.83, 0.21
-4.90, 0.47
-6.22, 1.04

a

β

Model 1: Age at SWAN visit, education, dietary fat intake, first degree family history of breast cancer, hormone therapy (HT) or oral
contraceptive (OC) use during study, OC use before baseline, race, age at menarche, and menopausal status
b

Model 2: Adjusts for variables included in Model 1, plus BMI

Table 7: Mean percent mammographic density (PMD) at earliest and latest observation and change in PMD by VMS experience
among women who naturally transitioned from pre/perimenopausal to postmenopausal (N=426); SWAN Mammographic Density
Study

Non-symptomatic (no VMS)
Symptomatic (any VMS)
Ever, infrequent (1-5 times in past two weeks)
Ever, frequent (6+ times in past two weeks)
a
b

N
(women)

Starting PMD a
Mean (SD) %

Ending PMD a
Mean (SD) %

95
331
153
178

43.5 (22.7)
42.0 (20.1)
41.8 (19.4)
42.2 (20.8)

37.3 (20.2)
35.7 (17.9)
36.5 (18.4)
35.1 (17.5)

Change in PMD
Adj. mean % b
P value
-5.3
-5.4
-4.8
-6.1

Ref
0.97
0.69
0.65

Starting PMD is PMD at earliest observation; ending PMD is PMD at latest observation.

Least squares means adjusted for: age at SWAN enrollment, age at first birth, use of HT or OC before baseline, use of HT or OC
during the study period, BMI at baseline, alcohol use at baseline, menopausal status at baseline, education, dietary fat intake, first degree
family history of breast cancer, age at menarche, starting PMD, and time difference between starting and ending PMD.

Figure 1: Risk estimates and 95% confidence intervals for the association between VMS and percent mammographic density by
menopausal status and hormone therapy use (N=833)
HT, hormone therapy; P, progestin; E/P, estrogen/progestin

CHAPTER 3
MENOPAUSAL VASOMOTOR SYMPTOMS AND INCIDENT BREAST CANCER RISK
IN THE STUDY OF WOMEN’S HEALTH ACROSS THE NATION

3.1 Abstract
Two case-control studies have reported a 50% decreased breast cancer risk among
women who experienced menopausal vasomotor symptoms (VMS), but one cohort study found
no association. VMS may be triggered by declining estrogen levels during menopause, whereas
elevated estrogen levels have been associated with increased breast cancer risk. VMS may thus
be indicative of lower susceptibility to breast cancer.
We evaluated this relationship in the longitudinal Study of Women’s Health Across the
Nation (SWAN), which collected annual data on VMS, endogenous hormone levels, and breast
cancer occurrences in 3,098 women who were pre- or early perimenopausal at enrollment. We
evaluated the relation of VMS to breast cancer risk using discrete survival analysis.
Over an average 11.4 years of follow-up, 129 incident breast cancer cases were selfreported, and approximately 50% of participants experienced VMS. Symptomatic women had a
reduced risk of breast cancer compared to non-symptomatic women (OR 0.62, 95% CI 0.39,
0.99). The association was stronger in the subgroup of women who fully transitioned to
postmenopause during follow-up (N=80 cases, OR 0.45, 95% CI 0.26, 0.77). Associations were
unchanged with adjustment for endogenous hormone levels.
VMS appear to be a marker of reduced breast cancer risk. Our findings may suggest a
more limited role of endogenous hormones in this association than previously hypothesized.
Future research is needed to understand the biology underlying this relationship.
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3.2 Introduction
Two recent case-control studies found an approximate 50% reduction in breast cancer
risk for women who reported any menopausal vasomotor symptoms (VMS), defined as hot
flashes and/or night sweats, prior to their diagnosis compared to those who did not (39, 40).
However, this provocative result was not supported by a recent, large, prospective cohort study
(63). A clear inverse relationship between VMS and breast cancer risk could identify an easily
measurable factor that may be used to enhance current risk prediction methods. The inconsistent
findings from previous studies warrant further prospective investigation of this relationship.
An inverse relationship between VMS and breast cancer risk is plausible, given the
common hormonal mechanisms underlying both VMS and breast carcinogenesis. Many
identified breast cancer risk factors are associated with an increased lifetime exposure to sex
hormones, particularly estrogen, such as early menarche, lower parity, and late age at menopause
(80, 81). Further, use of certain exogenous hormone therapies has been shown to increase risk
(82). While the exact etiology remains unclear, dramatic fluctuations in endogenous sex
hormones during the menopausal transition may trigger the onset of VMS (45, 83, 84).
Exogenous hormone therapy is effective in relieving VMS in many women (46), implying that
hormone levels may be important to the management and etiology of VMS.
Prior studies have not adjusted for endogenous sex hormone levels to determine the
extent to which an association between VMS and breast cancer risk is mediated by hormone
levels (39, 40, 63). We prospectively investigated this association in the longitudinal Study of
Women’s Health Across the Nation (SWAN), a large, racially/ethnically diverse cohort of women
who have been followed across the menopausal transition, and on whom annual demographic,
reproductive, and endogenous sex hormone data are available. We hypothesized that menopausal
VMS would be associated with reduced breast cancer risk. We further hypothesized that this
association would be attenuated after adjustment for endogenous sex hormone levels.
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3.3 Methods
3.3.1 Study population
The design and recruitment procedure of the SWAN cohort has been described in detail
elsewhere (54). Briefly, the study enrolled women from seven locations during 1996-1997, with
some locations oversampling from different racial groups to create a diverse cohort. Women
were aged 42-52 years at enrollment and were pre- or early perimenopausal (i.e., bleeding within
the last three months). Women using hormone therapy or oral contraceptives in the prior three
months were excluded from enrollment, as were women who were pregnant or breastfeeding or
who did not have an intact uterus and at least one ovary. In total, 3,302 women were enrolled and
each provided written consent at the location of recruitment. All sites obtained institutional
review board approval for the study protocol. Annual follow-up visits are on-going and include
clinical assessments and questionnaires. Data through follow-up visit 13 are currently available.
The current study uses data from the full SWAN cohort. We excluded 21 women with a
history of breast cancer at enrollment and a further 183 women who did not participate in any
follow-up visits beyond the baseline enrollment visit and therefore had no incident breast cancer
information. Women who reported that they were pregnant or breastfeeding during the study
period were excluded for those specific visits (four women, five study visits). After these
exclusions, the study population included 3,098 women who contributed data from 34,905
SWAN visits.

3.3.2 Vasomotor symptom assessment
At the baseline and each annual follow-up visit, SWAN participants reported the
frequency of VMS in the prior two weeks via a self-administered questionnaire in the language
appropriate to the participant (English, Spanish, Cantonese, or Japanese) using a standard
questionnaire. Questions related to hot flashes and night sweats were worded as follows:
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“Thinking back over the last two weeks, how often have you had hot flashes or flushes / night
sweats?” Response categories were: not at all, 1-5 days, 6-8 days, 9-13 days, every day.
Consistent with previous analyses in the SWAN cohort (55-57), women who reported any hot
flashes or night sweats (versus not at all) were classified as being symptomatic of VMS at that
visit. Women who reported having hot flashes or night sweats on 6 or more days in the last two
weeks were classified as being symptomatic of frequent VMS at that visit (38), while women who
reported having hot flashes or night sweats 1-5 days in the last two weeks were classified as being
symptomatic of infrequent VMS at that visit.

3.3.3 Breast cancer assessment
SWAN participants self-reported cancer history during the baseline enrollment interview.
At each subsequent follow-up, women were interviewed to assess their medication and health
status since the previous assessment. Interviews were administered by trained personnel in the
language appropriate to the participant (English, Spanish, Cantonese, or Japanese) using standard
interview questions. During the interview, women were asked if they had been told that they had
breast cancer by a health care provider since their last assessment. Responses were recorded as
“Yes,” “No,” or “Don’t know.”

3.3.4 Endogenous sex hormone assessment
Endogenous sex hormone and gonadotropin levels (estradiol, E2; sex hormone binding
globulin, SHBG; follicle stimulating hormone, FSH) were assessed using blood samples collected
from SWAN participants at each of their annual clinical assessments. Samples were collected in
the morning following a 12-hour overnight fast, and were scheduled within 2-5 days of the onset
of the menstrual cycle (the early follicular phase (EFP)) for pre- and perimenopausal women.
Two attempts were made to obtain an EFP sample. If a timed sample could not be obtained,
usually due to menstrual unpredictability during perimenopause, a random fasting sample was
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taken within 90 days of the annual SWAN visit date. Blood samples were refrigerated prior to
centrifugation, which was performed 1-2 hours after the blood draw (85). Serum was shipped to
a central laboratory (SWAN Central Ligand Assay Satellite Services Laboratory, University of
Michigan, Ann Arbor, MI) for processing. Assays were performed on the ACS-180 automated
analyzer (Bayer Diagnostics Corporation); the assay protocol has been described in detail
elsewhere (86). All assay processing was blinded with respect to VMS and breast cancer status.
Inter-assay and intra-assay coefficients of variation (CV) were 6.4% and 10.6% respectively for
E2, 12.0% and 6.0% respectively for FSH, and 9.7% and 11.3% respectively for SHBG (87).

3.3.5 Covariate assessment
Information on covariates was collected during the baseline and annual SWAN follow-up
visits as part of the clinical assessment or by interviewer- or self-administered questionnaires.
Demographic and reproductive variables that were considered unchanging in the current analysis
included: race/ethnicity, education, age at first birth, age at menarche, age at menopause (if
observed), alcohol consumption, physical activity, active and passive smoking exposure, dietary
fat and fiber intake, and SWAN site. Covariates that were considered time-varying and updated
at each follow-up visit included: menopausal status, body mass index (BMI), parity, family
history of breast cancer, hormone therapy use, bilateral oophorectomy or hysterectomy, sex
hormone levels, and cycle day of blood draw for hormone level assessment (day 2-5 versus
other).
Menopausal status was classified in accordance with standard SWAN protocol (54):
women with no change in menstrual regularity over the past year were considered
premenopausal; women with decreased menstrual regularity who had had a menstrual period in
the past three months were considered early perimenopausal; women with no menstrual bleeding
in the 3-11 months before the interview date were considered late perimenopausal; and those with
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no bleeding in the last 12 months were considered postmenopausal. Early and late
perimenopause were collapsed into a single perimenopausal category for this analysis. Women
who reported bleeding in the previous 12 months and reported hormone therapy (HT) use in the
previous year were classified as unknown menopausal status due to HT use for those visits.
Postmenopausal women remained classified as such if HT use was initiated after the final
menstrual period. Women reporting a hysterectomy or bilateral oophorectomy were classified as
postmenopausal starting at the visit at which the surgery was reported.
By study design, women were not taking HT at baseline enrollment. At each follow-up
interview, women were asked to report the use of estrogen, progestin, or combination
estrogen/progestin hormone therapy since their last study visit. When possible, interviewers
verified medication from the container label. Lifestyle variables, including alcohol consumption,
physical activity, smoking, and dietary fat and fiber intake were assessed in accordance with
previous SWAN publications (38, 57, 62). Total alcohol consumption was categorized as: <1
drink/month, 1 drink/month - <2 drinks/week, 2+ drinks/week. Total physical activity was
assessed using a continuous variable that incorporated the proportion of the year in which activity
was performed, a standardized intensity score, and the duration of each bout of activity.
Development of the physical activity score has been described in detail in previous SWAN
publications (61). Smoking was categorized as: never smoked/no passive exposure, never
smoked/with passive exposure, former smoker, current smoker. Baseline dietary fat and fiber
intake were assessed using composite variables that reflected total average consumption based on
a validated food frequency questionnaire (88).

3.3.6 Statistical methods
After omitting study visits that occurred after a breast cancer diagnosis, a total of 31,712
observations from 3,098 participants contributed to the current analyses. Descriptive statistics
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included means and standard deviations for continuous variables and percentages for categorical
variables. We calculated relative risks of breast cancer diagnosis for baseline covariates using
logistic regression.
We assessed the longitudinal association between VMS and incident breast cancer risk
using logistic regression for discrete survival analyses. This statistical approach is appropriate for
data in which the outcome is recorded at discrete time intervals (i.e., SWAN visits) and the actual
date of the outcome is unknown (89). Women could contribute varying numbers of observations,
and observations were omitted after the visit at which the event occurred (i.e., the visit at which a
breast cancer diagnosis was reported) or continued to the end of the study period if no event
occurred. As in other survival analysis approaches, the inclusion of each interval in the dataset
was conditional on the participant having “survived” past the previous intervals. To avoid
temporal concerns with breast cancer treatment affecting VMS, we reverse-lagged the breast
cancer diagnosis to ensure that only VMS occurring before the diagnosis were considered (e.g., if
breast cancer was reported at visit 08, VMS and covariate information up to visit 07 were
included in the analysis).
To differentiate between symptomatic and non-symptomatic women, we modeled VMS
at each study visit as VMS reported at that visit or any prior visit. Therefore, a woman was
considered symptomatic from the first visit at which she reported VMS. Frequent VMS was
modeled similarly, meaning that a woman was considered symptomatic of frequent VMS from
the first visit at which frequent VMS was reported. HT use during the study period was modeled
in the same fashion. We developed the multivariable logistic regression models using the method
of best selection. Due to the limited number of breast cancer outcomes, we developed a
parsimonious model, retaining covariates only if they were significant in the model, or if their
exclusion resulted in a change in the odds ratio for the VMS exposure of 10% or more. Because
HT use may act as a confounder or intermediary in the relationship between VMS and breast
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cancer, we repeated our analysis among women who did not use HT during the study period. We
assessed interactions by race/ethnicity, HT use, BMI, and menopausal status using cross-product
terms.
To assess the effect of VMS through the complete menopausal transition on breast cancer
risk, we performed a secondary analysis of VMS during pre- or perimenopause and
postmenopausal breast cancer outcomes. This analysis was restricted to women who fully
transitioned to postmenopause without surgery during the study period and had a discernable final
menstrual period because they were not using HT (N=2,468). Only VMS reported during visits at
which the woman was pre- or perimenopausal and only breast cancer diagnoses reported during
visits at which the woman was postmenopausal were included in the analysis. Women reporting
pre- or perimenopausal breast cancer were censored at the visit before their breast cancer was
reported. A parsimonious multivariable model was built for this analysis using the same
methodology described above.
We performed a preliminary analysis to assess the association between sex hormone
levels and breast cancer risk in our study population. To evaluate the effect of sex hormone
levels on the association between VMS and breast cancer, we adjusted for each hormone (E2,
FSH, SHBG) individually in the multivariable model, as well as for all hormones together.
Because of the uncertain association between VMS and endogenous hormones and because
hormone levels fluctuated during perimenopause, we adjusted using several methods: hormone
level at the current visit, hormone level at the first perimenopausal visit, average hormone level
and change in hormone level over perimenopausal visits. Log transformations of hormone values
were used to satisfy normality assumptions. All but two women had endogenous hormone data
for at least one study visit. However, many women (N=2,579, 83%) had missing hormone data
during at least one follow-up. Overall, hormone data were captured for 25,806 of 31,712 study
visits (81%). Among visits in which women were pre- or perimenopausal, 63% of hormone data
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were captured during the first 2-5 days of menses (EFP) and we controlled for cycle day (day 2-5
or other) in all analyses. Hormone data were not available at the visit preceding diagnosis for 41
breast cancer cases, and these cases were excluded from the analysis that adjusted for hormone
level at the current visit.
Due to incomplete data collection, information from the New Jersey location was missing
for SWAN visits 07, 08, 10, and 11. This affected 345 study participants, including all Hispanic
women and one breast cancer case. We thus performed a sensitivity analysis by excluding all
women from the New Jersey location and comparing our results to those including these
participants.
All analyses were performed using SAS Version 9.2 (SAS Institute, Cary, North
Carolina).

3.4 Results
On average, women were approximately 46 years old at enrollment. The majority was
Caucasian (47%), with 29% African American, 17% Asian, and 7% Hispanic (Table 8). Most
women had completed some college education (76%). Over an average of 11.7 years of followup, 129 breast cancer cases were self-reported. Women who reported a breast cancer diagnosis
during follow-up were more likely to be Caucasian and college-educated. Overall, VMS were
reported at 51% of SWAN visits, and the frequency of ever having experienced VMS increased
from pre- to peri- and postmenopausal (32%, 56%, 52% of visits, respectively). More African
American women reported VMS than Caucasian and Hispanic women (63.2% versus 48.8% of
visits, p<0.01), while fewer Asian women reported VMS than Caucasian and Hispanic women
(40.6% versus 48.8% of visits, p<0.01).
We observed that symptomatic women had a 38% reduced risk of breast cancer
compared to non-symptomatic women (OR = 0.62, 95% CI 0.39-0.99) (Table 9). This

43

association was modified by race/ethnicity (pinteraction=0.07). After stratification, we found that the
relationship between VMS and breast cancer risk was strongest and statistically significant among
Caucasian women (OR = 0.45, 95% CI 0.22-0.79) (Table 9) and attenuated and non-significant
among African American and Asian women. We observed no significant interaction of the
protective relation of VMS with breast cancer by menopausal status (p=0.22), HT use (p=0.74),
or BMI (p=0.43). We found similar results when looking at infrequent versus frequent VMS,
although confidence intervals were wider due to smaller numbers of breast cancer cases in each
group.
In the secondary analysis of pre- and perimenopausal VMS and postmenopausal breast
cancer (N=2,468 women, 80 cases), we observed that symptomatic women had a significant 55%
reduction in risk of postmenopausal breast cancer compared to non-symptomatic women (OR =
0.45, 95% CI 0.26-0.77) (Table 10). We observed no significant interaction of this protective
relation by race/ethnicity (p=0.30), HT use (p=0.73), or BMI (p=0.42). Among women who
transitioned to postmenopause with no use of HT (N=1,348, 40 cases), results were similar
although non-significant (OR = 0.50, 95% CI 0.23-1.10) (Table 10).
Sex hormone levels were not statistically significantly associated with breast cancer risk
when adjusted for age, menopausal status, HT use, cycle day (day 2-5 or other), and SWAN visit
(OR = 1.17, 95% CI 0.91-1.49 for E2; OR = 0.83, 95% CI 0.64-1.09 for FSH; OR = 0.87, 95% CI
0.60-1.25 for SHBG). In the longitudinal analysis of VMS and breast cancer risk, adjustment for
hormone levels did not appreciably change the observed associations for symptomatic women
compared to non-symptomatic women (Table 11). These findings were consistent and nonsignificant among the 2,049 women with no HT use during the study period (Table 11). Results
were less precise but did not otherwise change when the observations of pre- and perimenopausal
hormone levels that were collected outside the EFP window were excluded from the analysis
(data not shown).
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Results of our analysis did not change after exclusion of women from the New Jersey
location. We have therefore presented results from the full study population.

3.5 Discussion
Three prior investigations have examined the relationship between menopausal VMS and
breast cancer risk (39, 40, 63). Our findings are consistent with two case-control studies that both
concluded an approximate 50% reduction in risk for women who experienced VMS at any point
during the menopausal transition (39, 40). However, a recent prospective investigation observed
no association between VMS and breast cancer risk (63). This study followed 11,297 women
with a mean age of 47.6 years at enrollment for an average of 13.7 years. During follow-up, 34%
reported hot flashes, 26% reported night sweats, and 348 incident breast cancer cases were
recorded. Participants were surveyed at three-year intervals and asked to report VMS in the past
12 months; thus VMS reporting was not captured for two out of every three years, and women
could contribute a maximum of six observations. It is likely that some short-term VMS were not
captured due to the infrequency of the data collection in this study. This may explain why the
percentage of women reporting VMS was considerably lower than general estimates of 50-80%
(35, 36, 38), and may have contributed to the observed null findings, particularly if VMS were
not recorded during perimenopause when symptoms were most frequent and severe (38). In
contrast, our study participants provided annual assessments of VMS over the past two weeks.
Although some VMS may still have been missed, this protocol was more likely to capture VMS
at least once during each menopausal stage, and allowed for up to 13 observations per woman.
Another unique feature of the present study was the inclusion of a racially/ethnically
diverse study sample. We found that the inverse relationship between VMS and breast cancer
risk was strongest among Caucasian women and weaker among African American and Asian
women. After stratification, the number of breast cancer cases in each racial/ethnic subgroup was
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limited (70, 32, and 26 cases for Caucasian, African American, and Asian, respectively). Low
statistical power may thus have contributed to the attenuated results among African American and
Asian women. It is interesting, however, that the association between VMS and breast cancer
risk was strongest among Caucasian women, despite the limited number of cases. Race/ethnicity
may influence self-reporting of VMS. African American women tend to self-report more
frequent (38) and severe symptoms than Caucasian women (77, 78), although these results have
not been consistent (90, 91). In contrast, Asian women have demonstrated less self-reporting of
VMS than Caucasian women in some studies (79). Consistent with these findings and previous
analysis of SWAN VMS data (38), African American women in our study reported more VMS
and Asian women reported fewer VMS than Caucasian women. Our findings suggest a
difference in the effect of VMS on breast cancer risk by race/ethnicity, but it is unclear if this is
due to true physiological differences, a lack of statistical power after stratification, or racial/ethnic
variation in the self-reporting of VMS.
We anticipated that the association between VMS and breast cancer risk may be related
to common hormonal etiologies; specifically, we hypothesized that any association would be
attenuated after adjustment for endogenous sex hormones. We observed a significant reduction in
breast cancer risk for women who experienced VMS, but contrary to our expectation, our results
were unchanged after adjustment for endogenous sex hormones. Sex hormone levels were not
statistically significantly associated with breast cancer risk in our study sample, although a
positive relationship between E2 and breast cancer, and inverse relationships between FSH and
SHBG and breast cancer are generally supported in the literature (92). The direction of our
observed associations was consistent with the literature, and our results could be explained by
low statistical power due to the small number of breast cancer cases. Additionally, 37% of preand perimenopausal hormone data in our study were collected outside the first 2-5 days of menses
(EFP), although considerable effort was made to collect blood samples during the EFP window
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(86). Excess variation in hormone levels may have still further reduced our statistical power,
despite controlling for cycle day and repeating analyses without observations collected outside
the EFP window.
On the other hand, our finding of minimal change in risk with hormone adjustment could
imply that the mechanism linking VMS to breast cancer is not strongly dependent on endogenous
hormone levels. While VMS have been associated with estrogen fluctuations during the
menopausal transition (42), these alone cannot account for the onset of symptoms. All women
experience a decline in estrogen during menopause, but not all women experience VMS (47).
Non-hormonal mechanisms such as changes in skin vasculature and central nervous system
regulation have been hypothesized to trigger VMS (45, 93). It is possible that non-hormonal
mechanisms that are important in both the onset of VMS and breast carcinogenesis could explain
our results. Future analyses in larger cohorts are needed to definitively determine the role of
endogenous hormones in mediating the observed relationship between VMS and breast cancer.
Our study was strengthened by the large, prospective, multi-racial/ethnic SWAN cohort
with annual assessment of demographic, reproductive, and clinical factors over up to 13 years of
follow-up. The results of our study must be interpreted within the context of its limitations,
however. Both VMS and breast cancer information were self-reported in our analysis. Previous
analyses in the SWAN cohort using our definition of presence and frequency of VMS have found
significant associations between VMS and lower bone mineral density, insulin resistance, and
subclinical cardiovascular disease (55-57). Self-report of breast cancer has been shown to be
valid in large epidemiologic studies (94, 95), but, along with the relatively small number of
incident breast cancer cases, did limit our capacity to look separately at invasive versus in situ
disease and at molecular subtypes.
Establishing VMS as a risk marker for incident breast cancer has considerable public
health implications. VMS are easily reportable without invasive or expensive procedures. An
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association between self-reported VMS and breast cancer risk could provide additional insight to
clinicians on the individual breast cancer risk of their patients. However, a better understanding
of the mechanisms underlying this association is needed before VMS may be suggested as an
enhancement to current risk prediction tools. Our findings may imply that hormonal pathways
have a lesser role in the association between VMS and breast cancer risk than previously
hypothesized. This result strongly justifies the need for future investigations to examine the
biological mechanisms linking the onset of VMS to breast cancer etiology.
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Table 8: Selected characteristics measured at baseline by breast cancer diagnosis
status (N=3,098); SWAN 1996-2013

General characteristics
Age, years: mean (std)
BMI, kg/m2: mean (std)
Underweight/normal: < 25
Overweight: 25 - < 30
Obese: 30+
Race/ethnicity
Caucasian
African-American
Asian
Hispanic
Education level
< High school
High school
College graduate
Post-college

No breast cancer
diagnosis
N = 2969

Breast cancer
diagnosis
N = 129

46.3 (2.69)

46.7 (2.73)

1.14

1.02, 1.28

28.2 (7.18)
1,201 (40.5)
796 (26.8)
939 (31.6)

28.8 (8.24)
51 (39.5)
24 (18.6)
52 (40.3)

1.01
Ref
0.60
1.39

0.96, 1.06
Ref
0.24, 1.49
0.64, 3.03

1,398 (47.1)
850 (28.6)
494 (16.6)
227 (7.7)

70 (54.3)
32 (24.8)
26 (20.2)
1 (0.7)

Ref
0.91
0.76
0.35

Ref
0.43, 1.96
0.31, 1.87
0.04, 2.97

195 (6.6)
517 (17.4)
957 (32.2)
598 (20.2)

4 (3.1)
14 (10.8)
40 (31.0)
33 (25.6)

0.72
Ref
1.56
2.63

0.08, 6.63
Ref
0.60, 4.02
1.01, 6.84

22 (17.1)

1.46

0.66, 3.26

49 (38.0)
38 (29.5)
37 (28.7)

Ref
0.61
0.78

Ref
0.28, 1.31
0.38, 1.62

55 (42.6)
74 (57.4)

Ref
1.20

Ref
0.65, 2.23

37 (28.7)
41 (31.8)
29 (22.5)
20 (15.5)

Ref
0.65
0.46
0.58

Ref
0.30, 1.40
0.20, 1.07
0.22, 1.56

67 (51.9)
61 (47.3)

Ref
0.66

Ref
0.35, 1.22

39 (30.2)
29 (22.5)
31 (24.0)
30 (23.3)

Ref
0.68
0.63
1.49

Ref
0.29, 1.62
0.26, 1.53
0.67, 3.34

29 (22.5)
12 (9.3)
57 (44.2)
31 (24.0)

Ref
0.42
0.79
1.29

Ref
0.11, 1.56
0.33, 1.89
0.51, 3.26

29 (22.5)
23 (17.8)
45 (34.9)
32 (24.8)
12 (9.3)
95 (73.6)

Ref
1.05
0.94
0.62
0.85
1.08

Ref
0.40, 2.78
0.39, 2.28
0.24, 1.65
0.25, 2.85
0.54, 2.19

Family history of breast cancer (mother or sister)
295 (9.9)
Physical activity score (tertiles)
<7.1
1,083 (36.5)
7.1 - <8.5
859 (28.9)
8.5+
906 (30.5)
Alcohol consumption (past year)
Non-drinkers
1,475 (49.7)
Drinkers
1,484 (50.0)
Smoking status
Never smoked / no passive exposure
855 (28.8)
Never smoked / passive exposure
841 (28.3)
Former smoker
759 (25.5)
Current smoker
488 (16.4)
Reproductive history
Menopausal status at baseline
Premenopausal
1,555 (52.4)
Early perimenopausal
1,345 (45.3)
Age at menarche (years)
< 12
698 (23.5)
12
777 (26.2)
13
798 (26.9)
14+
668 (22.5)
Age at first birth (years)
No children
503 (16.9)
< 20
492 (16.6)
20 - 29
1,392 (46.9)
30+
575 (19.4)
Number of live births
0
501 (16.9)
1
504 (17.0)
2
1,002 (33.7)
3+
955 (32.2)
Hormone therapy use before baseline (ever)
198 (6.7)
Oral contraceptive use before baseline (ever)
2,167 (73.0)
Percentages may not sum to 100% due to missing values
a
Relative risks adjusted for all selected baseline characteristics
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Relative risk a
OR
95% CI

Table 9: Odds ratio (OR) and 95% confidence intervals (CI) for the risk of breast cancer diagnosis;
SWAN 1996-2013

All women (N=3,098)
Non-symptomatic (no VMS)
Symptomatic (any VMS)
Ever, infrequent (1-5 times in past two weeks)
Ever, frequent (6+ times in past two weeks)

N
(events)
129
32
97
69
28

Fully adjusted a
OR
95% CI
Ref
0.62
0.59
0.70

Ref
0.39, 0.99
0.36, 0.97
0.39, 1.27

White women (N=1,468)
70
Non-symptomatic (no VMS)
22
Ref
Ref
Symptomatic (any VMS)
48
0.41
0.22, 0.79
Ever, infrequent (1-5 times in past two weeks)
36
0.41
0.21, 0.81
Ever, frequent (6+ times in past two weeks)
12
0.42
0.18, 0.97
a
Adjusted for age, SWAN visit number, age at first birth, BMI, first degree family history of breast
cancer, and hormone use during the study period

Table 10: Odds ratio (OR) and 95% confidence intervals (CI) for the risk of postmenopausal breast
cancer diagnosis among women who naturally transitioned to postmenopausal during the study period;
SWAN 1996-2013

All women (N=2,468)
Non-symptomatic (no VMS)
Symptomatic (any VMS)
Ever, infrequent (1-5 times in past two weeks)
Ever, frequent (6+ times in past two weeks)

N
(events)
80
24
56
21
35

Fully adjusted a
OR
95% CI
Ref
0.45
0.39
0.50

Ref
0.26, 0.77
0.20, 0.75
0.28, 0 90

No HT use during the study period (N=1,348)
40
Non-symptomatic (no VMS)
13
Ref
Ref
Symptomatic (any VMS)
27
0.50
0.23, 1.10
Ever, infrequent (1-5 times in past two weeks)
12
0.47
0.19, 1.21
Ever, frequent (6+ times in past two weeks)
15
0.52
0.22, 1.23
HT, hormone therapy
a
Adjusted for age at enrollment, SWAN site, age at first birth, BMI at baseline, family history of breast
cancer, and hormone use during study period

Table 11: Odds ratio (OR) and 95% confidence intervals (CI) for the risk of breast cancer diagnosis, adjusted for endogenous hormone
levels; SWAN 1996-2013

All women (N=3,096)
Non-symptomatic (no VMS)
Symptomatic (any VMS)
Ever, infrequent (1-5 times in past two weeks)
Ever, frequent (6+ times in past two weeks)

N
(events)
88
26
62
39
23

Original Model
Fully adjusted a
OR
95% CI
Ref
0.65
0.57
0.92

Ref
0.39, 1.09
0.33, 0.97
0.50, 1.69

Adj. for E2
OR
95% CI

Adj. for FSH
OR
95% CI

Adj. for SHBG
OR
95% CI

Ref
0.68
0.59
0.98

Ref
0.68
0.59
0.97

Ref
0.66
0.57
0.94

Ref
0.40, 1.13
0.34, 1.01
0.52, 1.82

Ref
0.41, 1.14
0.34, 1.02
0.52, 1.83

Ref
0.40, 1.10
0.33, 0.99
0.50, 1.75

No HT use during the study period (N=2,049)
61
Non-symptomatic (no VMS)
21
Ref
Ref
Ref
Ref
Ref
Ref
Ref
Ref
Symptomatic (any VMS)
40
0.71 0.40, 1.26
0.75 0.42, 1.34
0.74 0.41, 1.34
0.72 0.40, 1.30
Ever, infrequent (1-5 times in past two weeks)
28
0.66 0.36, 1.21
0.69 0.37, 1.28
0.69 0.37, 1.28
0.67 0.36, 1.23
Ever, frequent (6+ times in past two weeks)
12
0.87 0.41, 1.86
0.94 0.44, 2.05
0.92 0.42, 2.01
0.92 0.42, 1.97
E2, estradiol; FSH, follicle stimulating hormone; SHBG, sex hormone binding globulin; HT, hormone therapy
a
Adjusted for age, SWAN visit number, age at first birth, BMI, first degree family history of breast cancer, hormone therapy use during the study
period, and cycle day of blood draw (day 2-5 or other), and baseline hormone level
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